课题基金 / 基金详情

Prize - 202109PJT - Evaluating mutant NRAS as a molecular mediator of immunotherapy resistance in melanoma

Prize - 202109PJT - Evaluating mutant NRAS as a molecular mediator of immunotherapy resistance in melanoma
奖 - 202109PJT - 评估突变型 NRAS 作为黑色素瘤免疫治疗耐药性的分子介质
批准号：
460122
负责人：
Rose April A
金额：
$1.82万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-09-01 至 2022-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=460122&lang=en
关键词：
Biomarkers Immunotherapy Macrophage Mdsc Melanoma Next Generation Sequencing Nras Phenotype Switching Single Cell Rna Sequencing Tgf-Beta

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Metastatic melanoma is a devastating and deadly disease. Fortunately, great strides have been made in the treatment of melanoma and a number of effective treatments are now available to patients. Some of these treatments, including immunotherapies and tar
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金